Brought to you by 
AZ grants 3SBio exclusive Byetta and Bydureon rights in China
20 Sep 2017
Executive Summary
AstraZeneca PLC licensed 3SBio Inc. exclusive Chinese marketing rights to its diabetes products Byetta (exenatide) and Bydureon (once-weekly exenatide) (single dose tray, dual chamber pen, and auto-injector).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ grants 3SBio exclusive Byetta and Bydureon rights in China
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice